Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual disease.

Autor: Winter PS; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.; Institute for Medical Engineering & Science, MIT, Cambridge, MA, USA.; Department of Chemistry, MIT, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ramseier ML; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.; Institute for Medical Engineering & Science, MIT, Cambridge, MA, USA.; Department of Chemistry, MIT, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA., Navia AW; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.; Institute for Medical Engineering & Science, MIT, Cambridge, MA, USA.; Department of Chemistry, MIT, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA., Saksena S; Computer Science and Artificial Intelligence Laboratory, MIT, Cambridge, MA, USA.; Computational and Systems Biology Program, MIT, Cambridge, MA, USA., Strouf H; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA., Senhaji N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., DenAdel A; Center for Computational Molecular Biology, Brown University, Providence, RI, USA.; Department of Biostatistics, Brown University, Providence, RI, USA., Mirza M; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA., An HH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bilal L; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA., Dennis P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Leahy CS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Shigemori K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Galves-Reyes J; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.; Institute for Medical Engineering & Science, MIT, Cambridge, MA, USA.; Department of Chemistry, MIT, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA., Zhang Y; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.; Department of Biological Engineering, MIT, Cambridge, MA, USA., Powers F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Mulugeta N; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.; Institute for Medical Engineering & Science, MIT, Cambridge, MA, USA.; Department of Chemistry, MIT, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA., Gupta AJ; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA., Calistri N; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA., Van Scoyk A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Jones K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Liu H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Stevenson KE; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA USA., Ren S; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA USA., Luskin MR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Couturier CP; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.; Institute for Medical Engineering & Science, MIT, Cambridge, MA, USA.; Department of Chemistry, MIT, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA., Amini AP; Microsoft Research, Cambridge, MA, USA., Raghavan S; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Kimmerling RJ; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA., Stevens MM; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA., Crawford L; Center for Computational Molecular Biology, Brown University, Providence, RI, USA.; Department of Biostatistics, Brown University, Providence, RI, USA.; Microsoft Research, Cambridge, MA, USA., Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Current Address: Merck and Co., Rahway, NJ, USA., Manalis SR; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Biological Engineering, MIT, Cambridge, MA, USA., Shalek AK; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.; Institute for Medical Engineering & Science, MIT, Cambridge, MA, USA.; Department of Chemistry, MIT, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA., Murakami MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Jun 10. Date of Electronic Publication: 2024 Jun 10.